Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.65 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.60 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | CYP19A1 known ✓ | P11511 | 3/20 | 0.46 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30109432 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL19134095 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29595625 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11119743 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1348933 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11554457 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28349232 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9482465 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL22264600 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30455087 | 1.00 | HRH1 (0.65) | HRH1KCNH2LMNAALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1093 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122038537-A | Bacterial RNA normal-temperature preservation solution for sputum sample of tuberculosis patient | 北京市疾病预防控制中心 | 2026-05-15 | — | — | CN | claimed |
| CN-122039043-A | Pitting corrosion inhibitor @ GO-Al-based composite coating and preparation method and application thereof | 广东工业大学 | 2026-05-15 | — | — | CN | claimed |
| CN-122010316-A | High-mineralization sulfur-containing water slow-release treatment method, anti-biodegradation corrosion inhibitor and preparation method thereof | 南京华洲新材料有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-12618090-B2 | Method for increasing the extraction rate of chondroitin sulfate prepared from tilapia skull | GUANGDONG OCEAN UNIVERSITY (CN) | 2026-05-05 | — | — | US | claimed |
| CN-119797805-B | Nanometer seed crystal additive for UHPC and preparation method thereof | 江苏奥莱特新材料股份有限公司 | 2025-06-17 | — | — | CN | claimed |
| CN-120154634-A | Application of sea cucumber chondroitin sulfate in preparation of medicine for preventing or treating Alzheimer disease | 广东医科大学 | 2025-06-17 | — | — | CN | claimed |
| CN-120138637-A | Preparation method and application of composite cationic corrosion inhibitor based on critical micelle concentration regulation | 福州大学 | 2025-06-13 | — | — | CN | claimed |
| US-12324850-B2 | Compositions and methods for cleaning, decontamination and treating subjects exposed to chemical irritants | REFLEX RED STORM, LLC. (US) | 2025-06-10 | — | — | US | claimed |
| CN-120078026-A | Use of alkylpyridinium salts for controlling plant parasitic nematodes | 兰州大学 | 2025-06-03 | — | — | CN | claimed |
| CN-120005199-A | Degradable latex catheter material and production process thereof | 广东亿康医疗器械有限公司 | 2025-05-16 | — | — | CN | claimed |
| US-6238542-B1 | Water soluble brighteners for zinc and zinc alloy electrolytes | CITIBANK, N.A. | 2001-05-29 | — | — | US | claimed |
| EP-0711546-B1 | OPHTHALMIC SOLUTION BASED ON DICLOFENAC AND TOBRAMYCINE AND ITS APPLICATIONS | ALCON CUSI S A (ES) | 2001-01-03 | — | — | EP | claimed |
| EP-0592348-B1 | Pharmaceutical formulation comprised of polymyxin-trimethoprim and an anti-inflammatory drug for ophthalmic and optic topical use | CUSI LAB (ES) | 1998-01-07 | — | — | EP | claimed |
| US-5679665-A | Pharmaceutical formulation comprised of polymyxintrimethoprim and an anti-inflammatory drug for ophthalmic and otic topical use | LABORATORIOS CUSI, S.A. (ES) | 1997-10-21 | — | — | US | claimed |
| EP-0711546-A1 | OPHTALMIC SOLUTION BASED ON DICLOFENAC AND TOBRAMICINE AND ITS APPLICATIONS | LABORATORIOS CUSI, S.A. (ES) | 1996-05-15 | — | — | EP | claimed |
| EP-0661055-A1 | Pharmaceutical formulation containing clobetasone and tobramycin and applications thereof | LABORATORIOS CUSI, S.A. (ES) | 1995-07-05 | — | — | EP | claimed |
| EP-0592348-A1 | Pharmaceutical formulation comprised of polymyxin-trimethoprim and an anti-inflammatory drug for ophthalmic and optic topical use | LABORATORIOS CUSI, S.A. (ES) | 1994-04-13 | — | — | EP | claimed |
| EP-0012926-B1 | SOLUTIONS OF X-RAY CONTRAST AGENTS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1984-03-07 | — | — | EP | claimed |
| WO-1980001244-A1 | X-RAY CONTRAST MEDIA SOLUTIONS | BYKGULDEN LOMBERG CHEM FAB (DE) | 1980-06-26 | — | — | WO | claimed |
| US-3960724-A | BROWN COAL | NOVEX TALALMANYFEJLESZTO ES ERTEKESITO KULKERESKEDELMI RT. (HU) | 1976-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618090-B2 | Method for increasing the extraction rate of chondroitin sulfate prepared from tilapia skull | MMP2, MMP13, MMP14 | HRH1 3177/4885KCNH2 3528/4885HRH3 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.